Challenges of aortic valve stenosis #VHD scenarios: how to get the diagnosis right with @EACVIPresident
🗓️Thursday, 16 October 2025, ⏲️ 18:00 to 19:00 CEST #Webinar
Organiser: European Association of Cardiovascular Imaging (EACVI)
Register now: 👉https://t.co/Jr9L4KnQSj
🔥 New in @NatureMedicine
How do you communicate lifetime benefits expected with HFpEF therapies?
New data from 3 RCTs (#DELIVER#FINEARTS#PARAGON) estimate up to *5 years* of event-free survival w combination Rx
#GDMT for HFpEF has finally arrived!
🔗https://t.co/ozSx3UwkLN
Development of an Innovative Pipeline With Fusion, Digital Planning, and Three‐Dimensional Printing to Improve Mitral Valve Interventional Care - Man - 2025 - Echocardiography - Wiley Online Library https://t.co/DdwYZDIwTZ
📢 Results of our EASY-STOP study now presented #LBCT at #HeartFailure2025! A thread 🧵
1/ 🚀 First study to evaluate home-based #UNa using a POC sensor to guide loop diuretic downtitration in chronic #HeartFailure patients. #Cardiology#FOAMed
For all the passionate professionals for cardiovascular imaging, this is your opportunity to mingle with, to network with and to learn from a large community with expertise on 4 modalities. Take advantage and join us! https://t.co/wTYVMtJOQV
@iCorGTrias@imagen_sec
New from #ACC25: Dr. Nuccia Morici & colleagues report the results of ALTSHOCK-2, finding that early implantation of IABP does *not* reduce 60-day mortality in #heartfailure-related cardiogenic shock
#JACC 🧵 (1/4)
Would you discharge an eligible patient with HFrEF w/o one or more disease-modifying, life-saving medications?
How about if you knew the odds are 7-15 fold against them ever being initiated as an outpatient?
How about if you were contributing to 100K preventable ☠️s per year?
What is the likelihood that this RCT will meet its primary endpoint?
A Digital Platform to Optimize Guideline Directed Heart Failure Therapy: Rationale and Design of the AIM-POWER Trial - Journal of Cardiac Failure https://t.co/F1tXnoEOHX
@JCardFail@robmentz@texhern@HFSA
✅ When RCT protocol directed, a large proportion of patients with HFrEF are treated with quadruple GDMT
❌ In clinical practice, when left to clinician discretion, it is < 1 in 10 of patients eligible that are actually treated, even in settings with no cost/access barriers
HFmrEF/HFpEF can’t wait
Rx the 3 🏛️
SGLTi + nsMRA + GLP-1 RA (if obesity)
The optimal strategy is simultaneous or rapid sequence initiation to all eligible patients, without delay
@gcfmd@JavedButler1@DCRINews@JAMACardio
https://t.co/OsmCRZXMcK…
The clinical benefits of simultaneous or rapid initiation outweigh the potential risks in HFmrEF/HFpEF
Simultaneous or Rapid Initiation of Combination Therapy for Heart Failure With Preserved Ejection Fraction https://t.co/wOXFw0ySnq
@SJGreene_md@JavedButler1@JAMACardio